Biodexa Sells Subsidiary for £1

TL;DR

Biodexa selling off a subsidiary for just £1, likely to cut losses or refocus.

AI Summary

Biodexa Pharmaceuticals Plc announced on July 23, 2024, that it has entered into a binding agreement to sell its entire issued share capital in its subsidiary, Biodexa Pharmaceuticals Limited, to a third party. The transaction is expected to close on or before August 31, 2024, and will result in the company receiving a nominal consideration of £1.

Why It Matters

This sale represents a strategic divestment, allowing Biodexa to focus on its core operations and potentially streamline its business structure.

Risk Assessment

Risk Level: medium — The sale of a subsidiary for a nominal amount suggests potential underlying issues or a strategic shift that could impact the company's future performance.

Key Numbers

• £1 — Nominal Consideration (The price at which the subsidiary is being sold.)

Key Players & Entities

• Biodexa Pharmaceuticals Plc (company) — The reporting entity
• Biodexa Pharmaceuticals Limited (company) — The subsidiary being sold
• £1 (dollar_amount) — Nominal consideration for the sale
• July 23, 2024 (date) — Date of the announcement
• August 31, 2024 (date) — Expected closing date for the sale

FAQ

Key Financial Figures

• $5.0 million — ess release announcing the closing of a $5.0 million registered direct offering and concurre

Filing Documents

• x7222416k.htm (6-K) — 11KB
• ex99_1.htm (EX-99.1) — 18KB
• 0001214659-24-012828.txt ( ) — 30KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 6-K ___________________________ REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨ EXPLANATORY NOTE On July 23, 2024, Biodexa Pharmaceuticals PLC (the “Company”) issued a press release announcing the closing of a $5.0 million registered direct offering and concurrent private placement. A copy of the press release is furnished hereto as Exhibit 99.1 and incorporated herein by reference. The information included in this report on Form 6-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing. SUBMITTED HEREWITH Attached to the Registrant’s Form 6-K filing for the month of July 2024 is: Exhibit No. Description 99.1 Press release dated July 23, 2024. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC Date: July 23, 2024 By: /s/ Stephen Stamp Stephen Stamp Chief Executive Officer and Chief Financial Officer 3

View Full Filing

View this 6-K filing on SEC EDGAR